Reports Q1 revenue $8.21M, consensus $6.95M. “The first quarter reflected steady progress across our portfolio as we continue advancing our discovery and development programs,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “As we look ahead, we anticipate receiving Gilead’s development plan and budget for the herpesvirus program and will evaluate our cost and profit share opt-in decision by mid-2026 while continuing to advance ABI-6250 toward Phase 2 in hepatitis delta virus by year-end.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASMB:
- ASMB Earnings this Week: How Will it Perform?
- Assembly Biosciences price target raised to $43 from $39 at Guggenheim
- Assembly Biosciences Adopts 2026 Performance-Based Bonus Plan
- Assembly Biosciences Advances HSV-2 Drug ABI-1179 With Completion of Early-Stage Trial
- Assembly Biosciences files $400M mixed securities shelf